In breast cancer driven by gene amplification and overexpression of ErbB2, disruption of ErbB2-dependent signalling with either trastuzumab or the small-molecule tyrosine kinase inhibitor lapatinib is correlated with clinical efficacy. Here, ERBB2 is linked to breast carcinoma.